FindTrial
Sign In

Awake Craniotomy in Brain Glioma Resection-A Comparison Between Dexmedetomidine and Innovar

Awake Craniotomy in Brain Glioma Resection-A Comparison Between Dexmedetomidine and Innovar

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014329
Enrollment
Unknown
Registered
2018-01-06
Start date
2018-01-02
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Glioma

Interventions

Dexmedetomidine Group: Dexmedetomidine
Innovar:Innovar

Sponsors

Qilu hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: cardiovascular disease who belong to American Society of Anesthesiologists Grade II to III

Exclusion criteria

Exclusion criteria: allergic to the contrast medium, severe hypertension(systolic blood pressure>180mmHg or diastolic blood pressure >110mmHg), severe liver or kidney dysfunction, myocardial infarction, heart failure, arrhythmia, hyperthyroidism and uncontrolled diabetes.

Design outcomes

Primary

MeasureTime frame
Observer’s Assessment of Alertness/Sedation (OAA/S) scales;Itra-operative MAP value;—

Countries

China

Contacts

Public ContactDejie Liu

Qilu Hospital of Shandong University

ldj9741@163.com+86 18560083791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026